71486-43-6

Basic information

• Product Name: 1-(4-FLUOROPHENYL)CYCLOHEXANECARBONITRILE
• Synonyms: 1-(4-FLUOROPHENYL)CYCLOHEXANECARBONITRILE;1-(4-Fluorophenyl)cyclohexanecarbonitrile,90%;1-(4-Fluorophenyl)cyclohexanecarbonitrile, 90% 1GR;Cyclohexanecarbonitrile,1-(4-fluorophenyl)-
• CAS NO: 71486-43-6
• Molecular Formula: C₁₃H₁₄FN
• Molecular Weight: 203.26
• EINECS: 275-515-9
• Mol File: 71486-43-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 33-38 °C
• Boiling Point: 320.6 °C at 760 mmHg
• Flash Point: 138 °C
• Appearance: /
• Density: 1.0708 (estimate)
• Vapor Pressure: 0.000315mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: 1-(4-FLUOROPHENYL)CYCLOHEXANECARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-FLUOROPHENYL)CYCLOHEXANECARBONITRILE(71486-43-6)
• EPA Substance Registry System: 1-(4-FLUOROPHENYL)CYCLOHEXANECARBONITRILE(71486-43-6)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 36/37/39-26
• Hazardous Substances Data: 71486-43-6(Hazardous Substances Data)

Usage

Chemical Properties

yellow crystalline mass

InChI:InChI=1/C13H14FN/c14-12-6-4-11(5-7-12)13(10-15)8-2-1-3-9-13/h4-7H,1-3,8-9H2

Upstream product

• 459-22-3 4-fluorophenylacetonitrile 
• 111-24-0 1,5-dibromo-pentane 

Downstream Products

• 85014-02-4 cyclohexyl-(4-fluoromethyl)methanone 
• 1338349-06-6 1-benzyl-N-{[1-(4-fluorophenyl)cyclohexyl]methyl}piperidine-3-carboxamide hydrochloride 
• 1338349-17-9 tert-butyl 4-[{[1-(4-fluorophenyl)cyclohexyl]methyl}(methyl)carbamoyl]piperidine-1-carboxylate 
• 1338349-13-5 tert-butyl 4-{(2E)-3-[1-(4-fluorophenyl)cyclohexyl]prop-2-enoyl}piperidine-1-carboxylate 
• 1338349-04-4 1-benzyl-N-{[1-(4-fluorophenyl)cyclohexyl]methyl}piperidine-4-carboxamide 
• 1338349-03-3 N-{[1-(4-fluorophenyl)cyclohexyl]methyl}piperidine-4-carboxamide hydrochloride 
• 1338348-99-4 tert-butyl 2-({[1-(4-fluorophenyl)cyclohexyl]methyl}carbamoyl)piperidine-1-carboxylate 
• 1338348-98-3 tert-butyl 3-({[1-(4-fluorophenyl)cyclohexyl]methyl}carbamoyl)piperidine-1-carboxylate 
• 1338348-97-2 tert-butyl 4-({[1-(4-fluorophenyl)cyclohexyl]methyl}carbamoyl)piperidine-1-carboxylate 
• 1338349-19-1 1-benzyl-N-{[1-(4-fluorophenyl)cyclohexyl]methyl}-N-methylpiperidine-4-carboxamide oxalate 
• 1338349-16-8 1-(1-benzylpiperidin-4-yl)-3-[1-(4-fluorophenyl)cyclohexyl]propan-1-one fumarate 
• 1338349-14-6 tert-butyl 4-{3-[1-(4-fluorophenyl)cyclohexyl]propanoyl}piperidine-1-carboxylate 
• 1338349-07-7 1-benzyl-N-{[1-(4-fluorophenyl)cyclohexyl]methyl}piperidine-2-carboxamide hydrochloride 
• 1307812-19-6 4-(1-(4-fluorophenyl)cyclohexyl)butanoate 

Relevant articles and documents

Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2

N-Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) that play critical roles in inflammatory reactions, and FPR-specific interactions can possibly be used to facilitate the resolution of pathological inflammatory reactions. We here report the synthesis and biological evaluation of six pairs of chiral ureidopropanamido derivatives as potent and selective formyl peptide receptor-2 (FPR2) agonists that were designed starting from our lead agonist (S)-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]propanamide ((S)-9a). The new compounds were obtained in overall yields considerably higher than (S)-9a. Several of the new compounds showed agonist properties comparable to that of (S)-9a along with higher selectivity over FPR1. Molecular modeling was used to define chiral recognition by FPR2. In vitro metabolic stability of selected compounds was also assessed to obtain preliminary insight on drug-like properties of this class of compounds.

Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4- fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents

We synthesized and evaluated inhibitory activity against T-type Ca 2+ channels for a series of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl) butyl]piperidine-4-carboxamide derivatives. Structure-activity relationship studies have revealed that dialkyl substituents at the benzylic position play an important role in increasing inhibitory activity. Oral administration of N-[2-ethyl-2-(4-fluorophenyl)butyl]-1-(2-phenylethyl)piperidine-4-carboxamide (20d) lowered blood pressure in spontaneously hypertensive rats without inducing reflex tachycardia, which is often caused by traditional L-type Ca2+ channel blockers.